---
search:
  boost: 2 
---

# Antiarrhythmics

This is a subcategory of Cardiovascular Agents.

## Formulary

### Preferred

| Preferred    | Generic Name | Quantity | Time (Days) |
| :--------------- | :----------- | :------: | :---------: |
| Amiodarone 200mg <sup>QL</sup> | Amiodarone HCI Tab 200 MG| 816 | 102 |
| Disopyramide <sup>QL</sup>   | Disopyramide Phosphate Cap (all strengths) | 816 | 102 |
| Dofetilide       ||||
| Flecainide <sup>QL</sup>      | Flecainide Acetate Tab (all strengths excl 100 MG) | 306 | 102 |
| Flecainide <sup>QL</sup>      | Flecainide Acetate Tab 100 MG | 612 | 102 |
| Mexiletine <sup>QL</sup>      | Mexiletine HCI Cap (all strengths excl 150 MG) | 306 | 102 |
| Mexiletine <sup>QL</sup>      | Mexiletine HCI Cap 150 MG | 408 | 102 |
| Norpace CR <sup>QL</sup>       | Disopyramide Phosphate ER Cap (all strengths excl 150 MG) | 612 | 102 |
| Norpace CR <sup>QL</sup>       | Disopyramide Phosphate ER Cap R 150 MG | 408 | 102 |
| Propafenone ER <sup>QL</sup> | Propafenone SR Cap (all strengths) | 204 | 102 |
| Propafenone IR <sup>QL</sup> | Propafenone HCI Tab (all strengths) | 306 | 102 |
| Quinidine ER <sup>QL</sup>    | Quinidine Gluconate ER Tab (all strengths) | 612 | 102 |
| Quinidine IR <sup>QL</sup>    | Quinidine Sulfate Tab (all strengths) | 612 | 102 |

### Non-Preferred

| Non-Preferred    | Generic Name | Quantity | Time (Days) |
| :--------------- | :----------- | :------: | :---------: |
| Amiodarone 100mg and 400mg <sup>QL</sup> | Amiodarone HCI Tab (all strengths excl 200 MG) | Determined pursuant to PA | Determined pursuant to PA |
| Multaq                     ||||

## Length of Authorizations

365 Days

## All Authorizations 

Must be prescribed in accordance with FDA approved labeling

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** (or **90 days** for fibrates) with at least **one preferred** drug in the same drug class
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=21)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=12)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
